Thalia Therapeutics says patent granted for Miristen in China
Reuters says Thalia Therapeutics PLC has received a new patent grant for Miristen in China. Phase 1 results for Miristen are expected in H1 2027.
Reuters says Thalia Therapeutics PLC has received a new patent grant for Miristen in China. Phase 1 results for Miristen are expected in H1 2027.